Johnson & Johnson

In the Phase‑3 ICONIC‑PsA 1 study, ICOTYDE achieved an ACR20 rate of 58% at 16 weeks versus 41% with placebo; 29% reached ACR50 and no new safety signals were observed. The oral IL‑23R agent could be a more convenient alternative to injectable therapies and is also being tested in plaque psoriasis, ulcerative colitis and Crohn's disease. The stock quickly recovered its recent pullback and is trading near its prior high, supported by stable cash flows and new pipeline catalysts. » More on deraktionaer.de

Johnson & Johnson said 12 of 16 patients with advanced, measurable prostate tumors treated with investigational oral drug JNJ-6143 achieved a complete or partial response, a 75% objective response rate. The drug disrupts cancer cell function and triggers cell death, addressing a significant unmet need in advanced prostate cancer. Analysts called the data a potential "game-changer" for J&J's oncology franchise, and the company may disclose further development plans, including earlier-line studies, at its Dec. 8 Enterprise Business Review. » More on cnbc.com

Johnson & Johnson delivered solid third-quarter results: adjusted earnings per share beat expectations, revenue was about $25.4 billion, and the full-year outlook was raised. The stock initially fell but then turned higher. Twenty of 27 surveyed analysts still recommend buying, although several have slightly lowered their price targets (e.g., RBC, Guggenheim, Wells Fargo). Analysts point to weaker Darzalex pricing outside the U.S., drag from medical‑devices results, and growth coming from older products; Tremfya and Tecvayli beat expectations. » More on deraktionaer.de

Johnson & Johnson raised revenue in the third quarter of 2026 to about $25.4 billion (+6%), driven by a currency-adjusted increase of roughly 8% in the Innovative Medicine segment; MedTech grew moderately by about 2.5%. Reported net profit fell to around $0.2 billion (previous year: $5.2 billion), diluted earnings per share were about $0.09, and adjusted earnings per share were approximately $2.59 (previous year: $2.80). For the full year, the company slightly raised its outlook and now expects revenue of about $101–101.5 billion and adjusted earnings per share of roughly $11.1. » More on finanzen.net

Johnson & Johnson reported adjusted earnings of $2.59 per share and revenue up 5.9% to $25.4 billion, coming in above and in line with analysts' expectations, respectively. Management raised the full-year adjusted EPS guidance to $11.05–11.15 and the revenue midpoint to $101.2 billion. The medical devices unit grew just 2.5% while the pharmaceutical business rose 7.7%; the mixed performance and higher market expectations led to a share-price drop of almost 6%. Cited reasons include operational disruptions such as the war in Iran, as well as one-time charges and acquisitions. » More on deraktionaer.de